Prescient is an evidence-based decision-support partner to the pharmaceutical and biotech industries whose mission is to optimally shape new product, brand and mature product planning strategies.

Our diverse yet integrated skillsets and methodologies ensure our clients’ key decisions are objectively assessed from both a clinical and commercial perspective, resulting in differentiated products and offerings.


Shaping Decisions Driving Value

Our People

Prescient’s team consists of highly experienced executives who share our core values of thinking collaboratively, creatively and constructively. We effectively integrate different skills and perspectives into a single client-engagement team.

Our Approach

The format and scope of our engagements are customized to meet our clients’ needs and our ‘best-in-front’ team philosophy ensures access to the necessary levels of expertise and thinking.

Our Clients

We engage directly with a number of functions supporting new product, brand and mature product planning activities; to view a full list of these, please click the
link below.

Latest News

CUBE Tech Fair welcomes spectacular speakers

Ronald E. Blaylock elected to Pfizer's Board of Directors

Drugs similar to aspirin, ibuprofen could help treat sepsis, study suggests

Novartis drug Zykadia receives FDA Priority Review for first-line use in patients with ALK+ metastat …

Another record year for Bayer – good progress with the acquisition of Monsanto

Successful insomnia treatment may require nothing more than a placebo

Bristol-Myers Squibb appoints three new independent directors

Online pharmacies could fuel antibiotic resistance

Vitamin D protects against colds and flu, finds major global study

AstraZeneca enters agreement with TerSera Therapeutics for Zoladex in the US and Canada

Your computer can help scientists search for new childhood cancer treatments

DNA computer brings 'intelligent drugs' a step closer

Spider web of cancer proteins reveals new drug possibilities

Siliq (brodalumab) approved by the US FDA for adult patients with moderate-to-severe plaque psoriasi …

Boehringer Ingelheim and Weill Cornell Medicine announce new collaboration to discover next generati …

Delay to hep C drug program behind Merck's write-down decision, say analysts

AstraZeneca’s FDA delayed ZS-9 gains European thumbs-up

Patient death in phase 3 raises doubts about safety of Roche’s potential hemophilia blockbuster emic …

Celgene president, COO Jackie Fouse to make shock departure

J&J leads $25M Series A in targeted radiotherapy startup

Chutes & Ladders: FDA’s personalized medicine head leaves for Grail

Incyte pens cancer I-O pact with University of Pennsylvania’s cancer center

Aveo takes baby step forward for once-rejected tivozanib

Cyclacel AML drug fails phase 3, wiping 30% off stock

BMJ warns of global impact of Trump on R&D, regulation

ImmusanT's celiac disease immunotherapy passes first clinical test

Argos kidney cancer vax fails phase 3 futility review, future in doubt

Cancer startup PMV Pharma gains impressive $74M B round

After Merck KGaA rejection, Apitope advances MS drug on strength of phase 2a safety, lesion reductio …

VBL posts additional data from phase 2 thyroid cancer trial

Trump taking momentum out of healthcare stocks, says analyst

Revlimid approved for use against multiple myeloma in Europe

Bid to broaden Zykadia label given priority review status

Emicizumab trial death being investigated by Roche

India making major strides in vaccine development and safety

Daiichi Sankyo announces structural changes

Changes at the top for Celgene

Zydus Cadila approved to market VaxiFlu 4 in India

New company, Fusion Pharmaceuticals, set up in Canada

Former GSK neuroscience head named PureTech’s CMO

Auris aims to bounce back with King's collaboration

New data supports switching to Relvar/Breo Ellipta

Pernix rockets on patent litigation win

In Supreme Court, biosimilars industry briefs against more exclusivity

UCB’s mixed results and conservative guidance hit share price

Medical News Today: Dementia risk reduced by eating 'five-a-day'

Medical News Today: Anorexia: Deep brain stimulation may be an effective treatment

Medical News Today: Alzheimer's disease: Molecular study clarifies potential link to high blood …

Medical News Today: Waterpik vs. flossing: What is best?

Medical News Today: Gene mutations in brain linked to OCD-like behavior

Medical News Today: People with mental health disorders at risk of stroke, study finds

Medical News Today: Swollen uvula: Causes, symptoms, and remedies

Medical News Today: Eating 10 portions of fruits and veg daily best for health

Medical News Today: People who sleep longer twice as likely to develop dementia

Medical News Today: Skin health: Friendly bacteria keep harmful Staph in check

Medical News Today: Sexual side effects of antidepressants: Symptoms and treatment

Medical News Today: Periodontitis may be an early sign of type 2 diabetes

Medical News Today: Schirmer's test: What to expect with the dry eye test

Medical News Today: Eating fruits and vegetables reduces lung disease risk

Medical News Today: Genital herpes in pregnancy may raise autism risk for offspring

Manchester to explore new ways of paying for medicines

Better diabetic foot care 'could save NHS £250m'

Tickets available for Clinical Researcher of the Year – The Americas

Celebrating excellence in international clinical research

Novartis’ Afinitor gets NICE green light for kidney cancer

Mundipharma to launch Mabthera biosimilar in EU markets

Bowel scope screening cuts cancer and death rate

US priority review for Novartis’ lung cancer drug Zykadia

Priority review for Pfizer’s ALL drug

MSD, Wayra unveil Velocity Health winners

EU nod for Roche’s lung cancer drug Alecensa

Final NICE yes for Amicus’ Fabry disease drug

BMA report highlights NHS bed crisis

NHS books £886m year-to-date deficit

NICE draft guidelines reject Ipsen’s Cabometyx

More News